Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs in Diabetic Nephropathy
NCT04562025Phase 2Unknown
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic nephropathy (DN) comparing UC-MSCs treatment group with Placebo control group (2 arms). Primary endpoint: Incidence of Adverse Events at 48 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04562025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562025.